Tag: Portland
U.S. Patent Ruling Affirms Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation
PORTLAND, Ore., Nov. 21, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.
Paragon BioTeck Receives EN ISO 13485:2012 Certification
PORTLAND, Ore., March 29, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today that it has received EN ISO 13485:2012 certification, signifying the company's successful implementation of an effective quality management system.
Paragon BioTeck to Attend 34th Annual J.P. Morgan Healthcare Conference
PORTLAND, Ore., Jan. 7, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, January 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an environment of collaboration by bringing together stakeholders in the corporate, investor and financial sectors to learn about and explore market and sector trends.
